A carregar...
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk
BACKGROUND: Breast cancer molecular prognostic tools that predict recurrence risk have mainly been established on endocrine-treated patients and thus are not optimal for the evaluation of benefit from endocrine therapy. The Stockholm tamoxifen (STO-3) trial which randomized postmenopausal node-negat...
Na minha lista:
| Publicado no: | Breast Cancer Res Treat |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer US
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5668340/ https://ncbi.nlm.nih.gov/pubmed/28776283 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4428-9 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|